Lista de obras - Ingo Ringshausen - Dominio Público Uruguay

A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL.

artículo científico publicado en 2008

Antiapoptotic effect of interleukin-2 (IL-2) in B-CLL cells with low and high affinity IL-2 receptors.

artículo científico publicado en 2010

Antifungal therapy with itraconazole impairs the anti-lymphoma effects of rituximab by inhibiting recruitment of CD20 to cell surface lipid rafts.

artículo científico publicado en 2010

Cell cycle inhibition in malignant lymphoma: disease control by attacking the cellular proliferation machinery.

artículo científico publicado en 2006

Clinical challenge: fatal mucormycotic osteomyelitis caused by Rhizopus microsporus despite aggressive multimodal treatment.

artículo científico publicado en 2014

Combination therapy with brentuximab vedotin and cisplatin/cytarabine in a patient with primarily refractory anaplastic lymphoma kinase positive anaplastic large cell lymphoma.

artículo científico publicado en 2014

Constitutive activation of the MAPkinase p38 is critical for MMP-9 production and survival of B-CLL cells on bone marrow stromal cells

scientific article published on 01 December 2004

Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta.

artículo científico publicado en 2002

Cyclin E but not bcl-2, bax or mcl-1 is differentially expressed in ZAP 70-positive and ZAP 70-negative B-CLL cells.

artículo científico publicado en 2006

Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells.

artículo científico publicado en 2004

Drug-perturbation-based stratification of blood cancer

artículo científico publicado en 2017

Guideline for the treatment of chronic lymphocytic leukaemia: A British Society for Haematology Guideline

scientific article published on 15 July 2018

Immunotoxin BL22 induces apoptosis in mantle cell lymphoma (MCL) cells dependent on Bcl-2 expression

artículo científico publicado en 2009

Integration of innate into adaptive immune responses in ZAP-70-positive chronic lymphocytic leukemia.

artículo científico publicado en 2015

Lck is a relevant target in chronic lymphocytic leukaemia cells whose expression variance is unrelated to disease outcome.

artículo científico publicado en 2017

Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab.

artículo científico publicado en 2006

Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo.

artículo científico publicado en 2006

Mechanisms of apoptosis-induction by rottlerin: therapeutic implications for B-CLL.

artículo científico publicado en 2006

Molecular imaging for early prediction of response to Sorafenib treatment in sarcoma

artículo científico publicado en 2013

Notch2 controls non-autonomous Wnt-signalling in chronic lymphocytic leukaemia

scientific article published in Nature Communications

Oncogene-dependent tumor suppression: using the dark side of the force for cancer therapy.

artículo científico publicado en 2005

PET-MRI hybrid imaging in a rare case of B cell lymphoblastic lymphoma with musculoskeletal manifestation

artículo científico publicado en 2013

Predictive value of initial 18F-FLT uptake in patients with aggressive non-Hodgkin lymphoma receiving R-CHOP treatment

artículo científico publicado en 2011

Protein kinase c-β-dependent activation of NF-κB in stromal cells is indispensable for the survival of chronic lymphocytic leukemia B cells in vivo.

artículo científico publicado en 2013

Recruitment of PKC-betaII to lipid rafts mediates apoptosis-resistance in chronic lymphocytic leukemia expressing ZAP-70.

artículo científico publicado en 2009

Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1.

artículo científico publicado en 2011

Splenic sclerosing haemangioma causes false-positive finding at FDG-PET.

artículo científico publicado en 2010

Stromal cell protein kinase C-β inhibition enhances chemosensitivity in B cell malignancies and overcomes drug resistance

artículo científico publicado en 2020

Symmetric multifocal bone marrow involvement diagnosed by whole-body magnetic resonance imaging in a patient with B lymphoblastic lymphoma.

artículo científico publicado en 2012

The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in B-cell lymphomas through CD22 upregulation and PKC-βII depletion.

artículo científico publicado en 2011

The immunomodulatory drug Leflunomide inhibits cell cycle progression of B-CLL cells

scientific article published on 06 September 2007

Lista de obras de Ingo Ringshausen

A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL.

Antiapoptotic effect of interleukin-2 (IL-2) in B-CLL cells with low and high affinity IL-2 receptors.

Antifungal therapy with itraconazole impairs the anti-lymphoma effects of rituximab by inhibiting recruitment of CD20 to cell surface lipid rafts.

Cell cycle inhibition in malignant lymphoma: disease control by attacking the cellular proliferation machinery.

Clinical challenge: fatal mucormycotic osteomyelitis caused by Rhizopus microsporus despite aggressive multimodal treatment.

Combination therapy with brentuximab vedotin and cisplatin/cytarabine in a patient with primarily refractory anaplastic lymphoma kinase positive anaplastic large cell lymphoma.

Constitutive activation of the MAPkinase p38 is critical for MMP-9 production and survival of B-CLL cells on bone marrow stromal cells

Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta.

Cyclin E but not bcl-2, bax or mcl-1 is differentially expressed in ZAP 70-positive and ZAP 70-negative B-CLL cells.

Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells.

Drug-perturbation-based stratification of blood cancer

Guideline for the treatment of chronic lymphocytic leukaemia: A British Society for Haematology Guideline

Immunotoxin BL22 induces apoptosis in mantle cell lymphoma (MCL) cells dependent on Bcl-2 expression

Integration of innate into adaptive immune responses in ZAP-70-positive chronic lymphocytic leukemia.

Lck is a relevant target in chronic lymphocytic leukaemia cells whose expression variance is unrelated to disease outcome.

Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab.

Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo.

Mechanisms of apoptosis-induction by rottlerin: therapeutic implications for B-CLL.

Molecular imaging for early prediction of response to Sorafenib treatment in sarcoma

Notch2 controls non-autonomous Wnt-signalling in chronic lymphocytic leukaemia

Oncogene-dependent tumor suppression: using the dark side of the force for cancer therapy.

PET-MRI hybrid imaging in a rare case of B cell lymphoblastic lymphoma with musculoskeletal manifestation

Predictive value of initial 18F-FLT uptake in patients with aggressive non-Hodgkin lymphoma receiving R-CHOP treatment

Protein kinase c-β-dependent activation of NF-κB in stromal cells is indispensable for the survival of chronic lymphocytic leukemia B cells in vivo.

Recruitment of PKC-betaII to lipid rafts mediates apoptosis-resistance in chronic lymphocytic leukemia expressing ZAP-70.

Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1.

Splenic sclerosing haemangioma causes false-positive finding at FDG-PET.

Stromal cell protein kinase C-β inhibition enhances chemosensitivity in B cell malignancies and overcomes drug resistance

Symmetric multifocal bone marrow involvement diagnosed by whole-body magnetic resonance imaging in a patient with B lymphoblastic lymphoma.

The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in B-cell lymphomas through CD22 upregulation and PKC-βII depletion.

The immunomodulatory drug Leflunomide inhibits cell cycle progression of B-CLL cells